Pneumococcal conjugate vaccines (PCV) have reduced pneumococcal diseases glob-37 ally. Despite this, much remains to be learned about their effect on pathogen pop-38 ulation structure. Here we undertook whole genome sequencing of 660 pneumococ-39 cal strains from asymptomatic carriers to investigate population restructuring in 40 pneumococcal strains sampled before and after PCV13 introduction in a previously 41 vaccine-naïve setting. We show substantial decreasing frequency of vaccine-type (VT) 42 strains and their strain diversity post-vaccination in the vaccinated but not unvacci-43 nated age groups indicative of direct but limited or delayed indirect effect of vaccina-44 tion. Clearance of identical VT serotypes associated with multiple lineages occurred 45 regardless of their genetic background. Interestingly, despite the increasing frequency 46 of non-vaccine type (NVT) strains through serotype replacement, the serotype diver-47 sity was not fully restored to the levels observed prior to vaccination implying lim-48 ited serotype replacement. The frequency of antibiotic resistant strains was low and 49 remained largely unchanged post-vaccination but intermediate-penicillin-resistant 50 lineages were reduced in the post vaccine population. Significant perturbations marked 51 by changing frequency of accessory genes associated with diverse functions especially 52 mobile genetic elements and bacteriocin activity were detected. This phylogenomic 53 analysis demonstrates early vaccine-induced pneumococcal population restructuring 54 not only at serotype but also accessory genome level. 55 Author summary 56 Different formulations of PCVs have been effective in reducing the invasive pneu-57 mococcal disease burden globally. Clinical trials have started to indicate high im-58 pact and effectiveness of PCV13 in Sub Saharan Africa (SSA) but there is limited 59 understanding of how the introduction of PCVs alters the population structure of 60 pneumococcal strains at serotype and genomic level. Here we investigated this using 61 pneumococcal strains sampled pre-and post-PCV13 introduction from a previously 62 vaccine naïve setting in Northern Malawi. Our findings reveal decrease in frequency 63 of VT serotypes and their associated lineages in the largely vaccinated under-five 64 population but not older individuals indicating a direct but limited or delayed in-65 direct protection. The diversity of serotypes also decreased post-vaccination in VT 66 strains in the under-fives but there was no change in NVT strains suggesting incom-67 plete serotype replacement. At the genomic level, logistic regression revealed chang-68 ing frequency of accessory genes largely associated with mobile genetic elements but 69 2 such changes did not include any antibiotic resistance genes. These findings show 70 significant perturbations at serotype and accessory genome level in carried pneumo-71 coccal population after two years from PCV13 introduction but the pneumococcal 72 population was still perturbed and had not returned to a new equilibrium state. 73 Introduction 74 Pneumococcal polysaccharide antigens covalently attached to carrier proteins elicit 75 sufficient serotype-specific antibody responses against Streptococcus pneumoniae (the 76 pneumococcus) and form the basis of pneumococcal conjugate vaccines (PCV). Dif-77 ferent formulations of PCVs have been licensed and introduced globally, and clinical 78 case-control, cohort and surveillance studies have documented high effectiveness of 79 these vaccines on non-invasive [1] and invasive pneumococcal disease (IPD) [2]. For 80 example, after introduction of PCV7, 69% and 57% reductions in IPD were observed 81 in USA and UK respectively whereby vaccine type (VT) strains decreased by >90% 82 [2, 3]. Few African countries introduced PCV7 because its projected low coverage 83 of VTs as highly common invasive serotypes in this setting (e.g. serotypes 1 and 5) 84 were not covered [4]. Regardless, PCV7 caused >85% reduction in IPD in South 85 Africa, crucially in HIV-infected individuals [5]. Consistent with findings in high-86 income countries [6], higher-valent PCVs appears to be highly effective in reducing 87 VT serotypes in carriage (>65%) and IPD (>80%) in Africa[7-9]. 88 89
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Before After Maximum likelihood phylogeny of the carried pneumococcal strains reconstructed using core genome SNPs from 660 study strains demonstrating their genetic similarity and diversity. The strains' metadata namely GC (lineage), sampling period, age group and serotype category of the subjects shown by coloured strips around the phylogeny. The colours for phylogenetic branches correspond to the inferred GCs as shown in the metadata key next to the tree. The tree was rooted at the mid-point of the branch separating 'classical' nontypeable (NT) pneumococcal GC (GC15) from rest of the strains. Detailed characteristics of the study strains are provided in S1 Data. Frequency of VTs (%)
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Dynamics of pneumococcal GCs and serotypes. The leftward facing stacked bar graph shows frequency of GCs in under-fives while (b) the rightward facing bar graph shows frequency of GCs and their constituent serotypes in over-fives before and after PCV introduction. The bar graphs are aligned by genomic clusters (GC) for easy comparisons of frequency of serotypes pre-and post-vaccination between the two age groups. The serotypes are distinguished by different colours in the bar graphs as described in the key. GC23 is the 'bin' cluster consisting of unclustered strains not placed in clusters GC1-22. The GCs whose frequency changed significantly post-vaccination are marked with asterisks: P<0.05 (*) and P<0.01 (**) and those with borderline significance P<0.095 (.). The Fisher's exact test was used to determine P-values. Number of SNPs on the x-axis and statistical significance (-log 10 P-value) for P-values and odds ratio for the association of accessory genes with different variables namely (d) age group, (e) serotype category and (f) sampling period. The points were coloured by adjusted P-values after correcting for multiple testing using Bonferroni method. 
